Abstract:Alcoholic hepatitis (AH) is an acute and severe form of alco1holic liver disease associated with high morbidity and mortality of 30-50% worldwide, severity ranging from asymptomatic derangement of liver biochemistries to fulminant liver failure or death. Rapidly progressing jaundice and coagulopathy in prolonged excessive alcohol abusers with or without fever, malnutrition, and tender liver are the clinical hallmarks. The prognostic models (Model for end-stage liver disease, Maddrey's discriminant function [MDF], age, serum bilirubin, INR, creatinine [ABIC], Glasgow Alcoholic Hepatitis Score [GAHS], Lille's Score) not only predict the short term mortality, but also guide the clinicians to choose appropriate specific therapy (corticosteroid or pentoxifylline) and as a stopping rule if there is no significant benefits of it. MDF Score is commonly followed in clinical practice, score of >32 would predict short term mortality of around 20-30% at 1 month and 30-40% within 6 months after presentation. The GAHS on day 1 can predict 28 day overall survival outcome accuracy of 81%, which is comparatively higher than MDF Score. Moreover, ABIC Score categorizes risk of deaths (based on 90 days) into low risks (0%), intermediate risk (30%), and high risk (75%). Corticosteroid and pentoxifylline have significant benefits in decreasing mortality (corticosteroid improves survival on 28 day and 84 day of 78% and 59%) in severe disease state (MDF >32 or Lille's Score >0.45 or GAHS >9). Corticosteroid is the initial treatment of choice with infections screening before initiating; however, pentoxifylline is better preferred in case of AH with severe infections and hepatorenal syndrome. Additionally, combination of corticosteroids and N-acetylcysteine decreases development of hepatorenal syndrome, infections, and short-term mortality. However, the Lille Score after corticosteroid therapy of >0.45 after day 7 indicates poor responders or >0.56 indicates null responders. Therefore, in these cases, either therapy has to be stopped or changed to pentoxifylline. In treatment failure cases, liver transplantation is the ultimate option. However, the facilitating of this service in most transplant centers is a challenge. Beside these specific therapies, alcohol abstinence and recommendation of nutritional supplements with high calorie, protein diet and vitamin E, C, thiamine regardless of other treatment plays a prime role in preventing disease progression and survival benefits even in pre and post-transplant cases.

Diagnosis of Alcohol Use Disorder and Alcohol-Associated Liver Disease

Treatment of Alcohol Use Disorder: Behavioral and Pharmacologic Therapies

Alcohol use disorder in community management of chronic liver diseases

Diagnosis and Treatment of Alcohol‐Associated Liver Diseases: 2019 Practice Guidance From the American Association for the Study of Liver Diseases

Alcohol-associated liver disease - a current overview

Alcohol-associated liver disease – global epidemiology

Reducing the Global Burden of Alcohol-Associated Liver Disease: A Blueprint for Action

Barriers to Alcohol Use Disorder Treatment in Patients with Alcohol-Associated Liver Disease

Multidisciplinary Care of Alcohol-related Liver Disease and Alcohol Use Disorder: A Narrative Review for Hepatology and Addiction Clinicians

Alcohol-associated liver disease: A review on its pathophysiology, diagnosis and drug therapy

ACG Clinical Guideline: Alcohol-Associated Liver Disease

Management of Alcohol-Associated liver disease and alcohol use disorder in liver transplant candidates and recipients: Challenges and opportunities

Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease

Designing clinical trials to address alcohol use and alcohol-associated liver disease: an expert panel Consensus Statement

Early detection of liver disease in patients with alcohol use disorder improves long-term abstinence

Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease

A Prognostic Evaluation and Management of Alcoholic Hepatitis

Noninvasive Tests in Assessment of Patients with Alcohol-Associated Liver Disease

Integrated Multidisciplinary Care Model to Manage the Dual Pathology of Alcohol Use Disorder and of Liver Disease

Management of alcohol withdrawal syndrome in patients with alcohol-associated liver disease

Changing landscape of alcohol‐associated liver disease in younger individuals, women, and ethnic minorities